A two-step model of age-associated autoreactivity: B cell-intrinsic aging meets inflammaging.
Key claim: Aging progressively relaxes B cell-intrinsic central and peripheral tolerance, and inflammaging then selectively expands inflammation-adapted autoreactive B-cell subsets (including ABCs/DN2), linking immune senescence to autoimmunity.
Abstract
Aging is associated with declining protective immunity and increased autoreactivity, yet the mechanisms linking these processes remain incompletely understood. B lymphocytes are central to this paradox because they integrate antigen recognition, innate signaling, and differentiation under tightly regulated tolerance checkpoints. This review advances the hypothesis that aging appears to drive a progressive, B cell-intrinsic relaxation of central and peripheral tolerance, leading to the accumulation of autoreactive clones. These defects are reinforced by transcriptional, epigenetic, metabolic, and signaling remodeling that durably reshapes B-cell responsiveness. In parallel, chronic low-grade inflammation (inflammaging) acts as a selective pressure that preferentially expands inflammation-adapted B-cell subsets, including age-associated B cells (ABCs) and related DN2 populations, rather than uniformly activating the B-cell compartment. This synergy promotes extrafollicular differentiation while bypassing key germinal-center tolerance checkpoints, thereby enriching for autoreactive B-cell states. A unifying model is proposed in which intrinsic aging establishes susceptibility, whereas inflammaging amplifies pathogenic B-cell programs, linking immune senescence to autoimmunity and highlighting potential targets for selective therapeutic intervention.
Why this matters
Age-related autoimmunity has usually been narrated either as generic inflammaging or as adaptive-immune exhaustion; this review pins it on a specific interaction between B cell-intrinsic tolerance breakdown and inflammation-driven expansion of ABC/DN2 subsets. It gives the vault a named B-cell node connecting immunosenescence to autoimmune disease risk, and a concrete cell population (ABCs/DN2) that any future intervention claiming to modulate immune aging would need to move. As a hypothesis synthesis it is conceptual scaffolding rather than causal evidence, and no anti-ABC intervention has shown geroprotective or autoimmunity-modifying effects in humans.